I have heard back that a number of people have contacted the call center at Dendreon (877-336-3736) and been told to call back at a later date for specific information about getting treatment. I have spoken with Dendreon and they have explained that they are working with the various infusion centers on mapping out specific [...]
Provenge has finally received the long awaited approval from the FDA!!! We all celebrate and look forward to benefiting from its potential to extend our life. Provenge is the first immunologic therapy ever approved in the United States to treat cancer. (In Russia, Antigenics has received approval for an immunological treatment for kidney cancer). The [...]
More news from the AACR Annual Meeting Cruciferous vegetables, we all know them and some of us love them. What we know is that they need to form a part of the standard prostate cancer diet, but some early research shows that a substance found in the them can make prostate cancer cells even more [...]
ABC News has posted a brief story about Provenge. Most of us hope that sometime this week the FDA will finally approve Provenge. To see the brief video interview about Provenge click here. Joel T Nowak, MA, MSW
There were many themes running through the recent American Association of Cancer Researchers (AACR) conference that I just attended in Washington D.C. One significant theme running through the conference was the need to develop personalized medicine to be able to successfully control cancer. This leads us to the question, What is personalized medicine? [...]
It was announced today that the phase I/II trial of MDV3100 demonstrated positive results. MDV3100 is a novel triple-acting oral androgen receptor antagonist, the common antagonist most of us are familiar with today is Casodex. These results were published in the online April 15 version of The Lancet. […]
Researchers at the Department of Urology, Centre Hospitalier Universitaire du Québec (CHUQ), Quebec, Canada evaluated the rate and duration of prostate-specific antigen (PSA) response to high-dose bicalutamide (150 mg) in men with non-metastatic castration-resistant prostate cancer (nmHRPC) as well as its impact on the duration of metastasis-free survival. They concluded that high dose bicalutamide is [...]
Listening in on the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) Reviewing Evidence on the use of Radiation Therapy for Localized Prostate Cancer
Thanks to Kathy Meade, I just viewed an exceptional video about advanced prostate cancer. It also includes information on bone health, screening, research, the need for funding and the history of prostate cancer treatment. All advocates and men with prostate cancer should learn something by watching the video. The following is the link: http://www.itvisus.com/programs/hbhm/index.asp#ooid=Iza2VhMTqn-tHgaxfstDRMBJ 1b12EW7i [...]
According to a new position paper from the North American Menopause Society (NAMS), despite all the new drugs that are available, diet and lifestyle should remain the first osteoporosis management tool. Only after diet and lifestyle has failed should any of the newly approved treatment options to prevent osteoporosis be considered. […]
